Biosimilar Firms Say Irish Price Deal Hinders Uptake, As Govt Plans New Policy Measures

The Irish health ministry is planning measures to boost the prescribing of biosimilar medicines, but companies marketing biosimilars say that the pricing agreement signed last year by the originator industry and the government has served to hinder uptake of their products.

Reducing costs
Ireland is banking on biosimilars to reduce drug costs

More from Biosimilars

More from Biosimilars & Generics